MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer

International Journal of Cancer

Volumn 135, Issue 6, 2014, Pages 1356-1368

  Bai, Wen Dong ^a   Ye, Xing Ming ^a   Zhang, Meng Yao ^a   Zhu, Hua Yu ^a   Xi, Wen Jin ^a   Huang, Xun ^a   Zhao, Jiao ^a   Gu, Bin ^a   Zheng, Guo Xu ^a   Yang, An Gang ^a   Jia, Lin Tao ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

miR 200c; TGF ; trastuzumab resistance; ZEB1; ZNF217

Indexed keywords

MICRORNA 200C; PROTEIN ZNF217; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER RESISTANCE; CARCINOGENICITY; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; INHIBITION KINETICS; METASTASIS; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TUMOR INVASION;

MIR-200C; TGF-Β; TRASTUZUMAB RESISTANCE; ZEB1; ZNF217;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MICE, NUDE; MICRORNAS; NEOPLASM METASTASIS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904065393     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28782     Document Type: Article

References (37)

1. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN,. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608: 1-22.
2. Hudis CA,. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
3. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
4. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 1800-8.
5. Korkaya H, Kim GI, Davis A, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell 2012; 47: 570-84.
6. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
7. Polyak K, Weinberg RA,. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-73.
8. Sabe H,. Cancer early dissemination: cancerous epithelial-mesenchymal transdifferentiation and transforming growth factor beta signalling. J Biochem 2011; 149: 633-9.
9. Huang S, Holzel M, Knijnenburg T, et al. MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. Cell 2012; 151: 937-50.
10. Wang SE,. The functional crosstalk between HER2 tyrosine kinase and TGF-beta signaling in breast cancer malignancy. J Signal Transduct 2011; 2011: 804236.
11. Massague J,. TGFbeta in Cancer. Cell 2008; 134: 215-30.
12. Vendrell JA, Thollet A, Nguyen NT, et al. ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion. Cancer Res 2012; 72: 3593-606.
13. Klymkowsky MW, Savagner P,. Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am J Pathol 2009; 174: 1588-93.
14. Yates LA, Norbury CJ, Gilbert RJ,. The long and short of microRNA. Cell 2013; 153: 516-19.
15. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601.
16. Dave N, Guaita-Esteruelas S, Gutarra S, et al. Functional cooperation between Snail1 and twist in the regulation of ZEB1 expression during epithelial to mesenchymal transition. J Biol Chem 2011; 286: 12024-32.
17. Gong C, Yao Y, Wang Y, et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 2011; 286: 19127-37.
18. Ulanet DB, Ludwig DL, Kahn CR, et al. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci USA 2010; 107: 10791-8.
19. Stephenson JR, Axelrad AA, McLeod DL, et al. Induction of colonies of hemoglobin-synthesizing cells by erythropoietin in vitro. Proc Natl Acad Sci USA 1971; 68: 1542-6.
20. Kim HJ, Kim WC,. Pretreatment tumor diameter/volume and pelvic lymph node status assessed by magnetic resonance imaging for uterine cervical carcinoma treated with concurrent chemotherapy and radiotherapy. J Obstet Gynaecol Res 2008; 34: 529-37.
21. Liu C, Kelnar K, Liu B, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011; 17: 211-5.
22. Singh A, Settleman J,. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741-51.
23. Burk U, Schubert J, Wellner U, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9: 582-9.
24. Lorusso G, Rüegg C,. New insights into the mechanisms of organ-specific breast cancer metastasis. Semin Cancer Biol 2012; 22: 226-33.
25. Garcia AG, Nedev H, Bijian K, et al. Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs. Oncogene 2013; 32: 2527-33.
26. Niikura N, Liu J, Hayashi N, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2012; 30: 593-9.
27. Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-90.
28. Fuchs BC, Fujii T, Dorfman JD, et al. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 2008; 68: 2391-9.
29. Yao Z, Fenoglio S, Gao DC, et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA 2010; 107: 15535-40.
30. Wu Y, Ginther C, Kim J, et al. Expression of Wnt3 activates Wnt/beta-catenin pathway and promotes EMT-like phenotype in trastuzumab- resistant HER2-overexpressing breast cancer cells. Mol Cancer Res 2012; 10: 1597-606.
31. Lesniak D, Sabri S, Xu Y, et al. Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer. PLoS One 2013; 8: e71987.
32. Miller TE, Ghoshal K, Ramaswamy B, et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008; 283: 29897-903.
33. Pencheva N, Tavazoie SF,. Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol 2013; 15: 546-54.
34. Xia H, Ooi LL, Hui KM,. MiR-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology 2013; 58: 629-41.
35. Park SM, Gaur AB, Lengyel E, et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894-907.
36. Yap TA, Omlin A, de Bono JS,. Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol 2013; 31: 1592-605.
37. Gunasinghe NP, Wells A, Thompson EW, et al. Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev 2012; 31: 469-78.